Molecular pathology of ovarian carcinomas

Virchows Archiv

Volumn 433, Issue 2, 1998, Pages 103-111

  Matias Guiu, Xavier ^a   Prat, Jaime ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Oncogenes; Ovary; Pathogenesis; Tumour suppressor genes; Tumours

Indexed keywords

CELL CYCLE PROTEIN; TELOMERASE;

APOPTOSIS; CELL DIFFERENTIATION; FAMILIAL CANCER; HUMAN; MALIGNANT TRANSFORMATION; MICROSATELLITE INSTABILITY; MUCINOUS CARCINOMA; ONCOGENE; ONCOGENE C ERB; ONCOGENE K RAS; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

BRCA2 PROTEIN; CYCLINS; FEMALE; GENES, BRCA1; GENES, ERBB-2; GENES, P53; GENES, RAS; HUMANS; MICROSATELLITE REPEATS; MUTATION; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 0031709216     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004280050224     Document Type: Review

References (100)

1. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Järvinen H, Powel SM, Jen J, Hamilton SR, Peterson GM, Kinzler KM, Vogelstein B, de la Chapelle A (1993) Clues to the pathogenesis of familial coloreclal cancer. Science 260:812-816
2. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie S, Yin S, Bast RC (1990) Overexpression of Her-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50:4087-4091
3. Bewtra C, Watson P, Conway T, Read-Hippee C, Lynch HT (1992) Hereditary ovarian cancer: a clinicopatholouical study. Int J Gynecol Pathol 11:180-187
4. Bicher A, Ault K, Kimmelman A, Gerhenson D, Reed E, Liang B (1997) Loss of heterozygosity in human ovarian cancer on chromosome 19q. Gynecol Oncol 66:36-40
5. Birrer MJ (1997) Discoveries in the cell cycle and ovarian cancer. Gynecol Oncol 64:187-188
6. Bosari S, Viale G, Radaelli V, Bossi P, Bonoldi E, Coggi G (1993) p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 24:1175-1179
7. Boyd J, Ruhin S (1997) Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol 64:196-206
8. Castilla LH, Couch FJ, Endos MR, Hoskins KF, Calzone K, Garher JF, Boyd J, Luhin MB, Destrano ML, Brody LC, Collins FS, Weber BL (1994) Mutations in the BRCA-1 gene in families with early breast and ovarian cancer. Nat Genet 8: 387-391
9. Chang F, Syrjänen S, Terahauta A, Syrjänen K (1993) Tumourigenesis associated with the p53 tumour suppressor gene. Br J Cancer 68:653-661
10. Cordon-Cardo, C (1995) Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 147:545-560
11. Cornells RS, Neuhausen SL, Johansson O, Arason A, Kelsell D, Ponder BAJ, Tonin P, Hamann V, Lindblom A, Lalle P, Longy M, Olah E, Scherneck S, Bignon J, Sobol H, Chang-Claude J, Larsson C, Spurr N, Borg A, Barkardottir RB, Narod S, Deville P (1995) High allele loss rates at 17q 12-q21 in breast and ovarian tumors from BRCA-1-linked families. Genes Chromosom Cancer 13:203-210
12. Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, Theillet C (1996) Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 69:247-253
13. Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J (1997) K-ras mutations in mucinous ovarian tumors. A clinicopathologic and molecular study of 95 cases. Cancer 79:1581-1586
14. Cuatrecasas M, Erill N, Musulen E, Costa I, Matias-Guiu X, Prat J. (1998) K-ras mutations in nonmucinous ovarian epithelial tumors: A molecular analysis and clinicopathological study of 144 patients. Cancer 82:1088-1095
15. Dodson MK, Cliby WA, Xu HJ, De Lacey KA, Hu SX, Keeney GL, Podratz KC, Jenkins RB, Benedict WF (1994) Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus. Cancer Res 54:610-613
16. Eltabakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR, Blumenson LE (1997) p53 Overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer 80:892-898
17. Enamoto T, Weghorsst C, Inoue M, Tanizawa O, Rice J (1991) K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 139:777-785
18. Englefield P, Foulkes WD, Campell IG (1994) Loss of heterozigosity on chromosome 22 in ovarian carcinoma is distal to and is not accompanied by mutations in NF at 22q12. Br J Cancer 70:905-907
19. Foster KA, Harrington P, Kerr J, Russell P, DiCioccio RA, Scott IV, Jacobs I, Chenevix G, Ponder BAJ, Gayther SA (1996) Somatic and germline mutations of the BRCA-2 gene in sporadic ovarian cancer. Cancer Res 56:3622-3625
20. Frank TS, Barton RE, Haefner HK, Roberts JA, Wilson MD, Hubbell GP (1994) Loss of heterozygosity and overexpression of the p53 gene in ovarian carcinoma. Mod Pathol 7:3-8
21. Friedman LS, Ostermeyer EA, Szabo C, Dowd P, Lynch ED, Rowell SE, King MC (1994) Confirmation of BRCA-1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 8:399-404
22. Fujita M, Enomoto T, Haba T, Nakashima R, Sasaki M, Yoshino K, Wada H, Buzard GS, Matsuzaki N, Wakasa K, Murata Y (1997) Alteration of p16 and p15 genes in common epithelial ovarian tumors. Int J Cancer 74:148-155
23. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshan K, Tartigian S, Bennett LM, Haugen Strano A, Swensen I, Miki Y, Eddington K, McClure M, Frye C, Weaver-Feldhaus K, Ding W, Gholami Z, Söderkvist P, Terry L, Jhanwar S, Berchuck A, Iglehart JD, Marks J, Ballinger DG, Barrett JC, Skolnick MH, Kamb A, Wiseman R (1994) BRCA-1 mutations in primary breast and ovarian carcinomas. Science 266:120-122
24. Gabra H, Taylor L, Cohen BB, Lessels A, Eccles DM, Leonard RCF, Smyth JF, Steel CM (1995) Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumors. Br J Cancer 72:367-375
25. Gibb RK, Taylor DD, Wan T, O'Connor DM, Doering DL, Gerçel-Taylor Ç (1997) Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cells lines. Gynecol Oncol 65:13-22
26. Haldane JS, Hird V, Hughes CM, Gullick WJ (1990) C-erb B-2 oncogene expression in ovarian cancer. J Pathol (Lond) 162:231-237
27. Hartman LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, Su JQ, Katzmann JA, Roche PC (1994) Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 12:64-69
28. Henriksen R, Wilander E, Oberg K (1995) Expression and prognostic significance of bcl-2 in ovarian tumors. Br J Cancer 72:1324-1329
29. Hiyama E, Gollahon L, Kataoka T, Kuroi K, Yokoyama T, Gazdar AF, Hiyama K, Piatyszek M, Shay JW (1996) Telomerase activity in human breast tumors. J Natl Cancer Inst 88:116-122
30. Hiyama K, Hiyama E, Ishioka S, Yamakido M, Inai K, Gazdar AF, Piatyszek MA, Shay JW (1995) Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 87:895-902
31. Hosking L, Trowsdale J, Nicolai H, Solomon E, Foulkes W, Stamp G, Signer E, Jeffreys A (1995) A somatic BRCA-1 mutation in an ovarian tumor. Nat Genet 9:343-344
32. Ionov YM, Peinado A, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutation in simple repeated sequences reveals a new mechanism for colonic carcinogenesis. Nature 363:558-561
33. Jacobs IJ, Smith SA, Wiseman RW, Futreal PA, Harrington T, Osborne RJ, Leech V, Molyneux A, Berchuck A, Ponder BAJ, Bast RC (1993) A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. Cancer Res 53:1218-1221
34. Kanuma T, Nishida J, Gima T, Barren JC, Wake N (1997) Alterations of the p16INK4A gene human ovarian cancers. Mol Carcinog 18:134-141
35. Katabuchi H, Tashiro H, Cho KR, Kurman RJ, Ellenson LE (1988) Micropapillarry serous carcinoma of the ovary: An immunohistochemical and mutation analysis of p53. Int J Gynecol Pathol 17:54-60
36. Katabuchi H, van Rees B, Lambers AR, Ronnett BM, Blazes MS, Leach FS, Cho KR, Hedrick L (1995) Mutations in DNA mismatch repair genes are not reponsible for microsatellite instability in most sporadic endometrial carcinomas. Cancer Res 55:5556-5560
37. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, Coviello GM, Wright WE, Wunrich SL, Shay JW (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015
38. Kim TM, Benedict WF, Xu HJ, Hu SX, Gosewehr J, Velicescu M, Yin E, Zheng J, D'Ablaing G, Dubeau L (1994) Loss of heterozygosity on chromosome 13 is common only in the biologically more agressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression. Cancer Res 54:605-609
39. King BL, Carcangiu ML, Carter D, Kiechle M, Pfisterer J, Pfleiderer A, Kacinski BM (1995) Microsatellite instability in ovarian neoplasms. Br J Cancer 72:376-382
40. Kirchweger R, Zeillinger R, Schneeberger C, Speiser P, Louason G, Theillet C (1994) Patterns of allele losses suggest the existance of five distinct regions of LOH on chromosome 17 in breast cancer. Int J Cancer 56:193-199
41. Klemi PJ, Takahashi S, Joensuu H, Kiilholma P, Naritmatsu E, Mori M (1994) Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int J Gynecol Pathol 13:228-233
42. Kobayashi K, Sagae S, Kudo R, Saito H, Koi S, Nakamura Y (1995) Microsatellite instability in endometrial carcinomas. Genes Chromosom Cancer 14:128-132
43. Koike M, Takeuchi S, Yokota J, Park S, Hatta Y, Miller CW, Tsuruoka N, Koeffler HP (1997) Frequent loss of heterozygosity in the region of the D7S523 locus in advanced ovarian cancer. Genes Chromosom Cancer 19:1-5
44. Kupryjanczyk J, Thor A, Beauchamp R, Merritt V, Edgerton SM, Bell DA, Yandell DW (1993) p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 90:4961-4965
45. Kupryjanczyk J, Bell D, Yandell DW, Scully RE, Thor AD (1994) p53 expression in ovarian borderline tumors and stage I carcinomas. Am J Clin Pathol 102:671-233
46. Kupryjanczyk J, Bell DA, Dimeo D, Beanchamp R, Thor AD, Yandell DW (1995) p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol 26:387-392
47. Li S-B, Schwartz PE, Lee W-H, Yang Feng TL (1991) Allele loss at the retinoblastoma locus in human ovarian cancer. J Natl Cancer Inst 9:637-640
48. Liu Y, Heyman M, Wang Y, Falkmer U, Hising C, Szekely L, Einhorn S (1994) Molecular analysis of the retinoblastoma gene in primary ovarian cancer cells. Int J Cancer 58:663-667
49. McMenamin ME, O'Neill A, Gaffney E (1997) Extent of apoptosis in ovarian serous carcinoma: relation to mitotic and proliferative indices, p53 expression, and survival. J Clin Pathol [Mol Pathol] 50:242-246
50. McManus DT, Yap EPH, Maxwell P, Russell SEH, Toner PG, McGee JOD (1994) p53 expression, mutation and allelic deletion in ovarian cancer. J Pathol (Lond) 174:159-168
51. Meden H, Marx D, Roegglen T, Schauer A, Kuhn W (1998) Overexpression of the oncogene c-erB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int J Gynecol Pathol 17:61-65
52. Merajner SD, Pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, Weber BL, Collins FS, Johnston C, Frank TS (1995) Somatic mutations in the BRCA-1 gene in sporadic ovarian tumors. Nat Genet 9:439-440
53. Miki Y, Swesen J, Shattuck-Eidens D, Futreal A, Harshman K, Tartigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey CH, Tran T, McClure M, Frye H, Hattier T, Phelps R, Hangen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bodgen R, Dyumanth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvening L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Canon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA-1. Science 266:66-71
54. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RCF, Kelly KF, Parkin DE, Haites NE (1993) p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 53:2128-2132
55. Murakami J, Nagai N, Ohama K, Tahara H, Ide T (1997) Telomerase activity in ovarian tumors. Cancer 80:1085-1092
56. Muto MG, Cramer DW, Tangir J, Berkowitz R, Mok S (1996) Frequency of BRCAI 185delAG mutation among Jewish women with ovarian cancer and matched population controls. Cancer Res 56:1250-1252
57. Naber SP, Tsutsumi Y, Yin S, Zolnay SA, Mobtaker H, Marks PJ, McKenzie SJ, DeLellis RA, Wolfe HJ (1990) Strategies for the analysis of oncogene activation. Studies of the new oncogene in breast carcinoma. Am J Clin Pathol 94:125-136
58. Narod SA, Madlensky L, Bradley L, Cole D, Tonin P, Rosen B, Risch HA (1994) Hereditary and familial ovarian cancer in southern Ontario. Cancer 74:2341-2346
59. Niwa K, Itoh M, Murase T, Morishita S, Itoh N, Mori H, Tamaya T (1994) Alteration of p53 gene in ovarian carcinoma, clinopathological correlation and prognostic significance. Br J Cancer 70:1191-1197
60. Offit K, Gilewski T, McGuire P, Schluger A, Hampel H, Brown K, Swensen J, Neuhausen S, Skolnick M, Norton L, Goldgar D (1996) Germline BRCA-1 185 del AG mutations in Jewish women with breast cancer. Lancet 347:1643-1645
61. Persons DL, Hartmann LC, Herath JF, Borell TJ, Cliby WA, Keeney GL, Jenkins RB (1993) Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas. Am J Pathol 142:733-741
62. Phelan CM, Rebbeck TR, Weber BL, Devilee P, Ruttledge MH, Lynch HT, Lenoir GM, Stratton MR, Easton DF, Ponder BA, Cannon-Albright L, Larsson C, Goldgar DE, Narod SA (1996) Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet 12:309-311
63. Pieretti M, Turker MS (1997) Mutation, ageing and ovarian cancer. Lancet 349:700-701
64. Pieretti M, Powell D, Gallion HH, Caze E, Conway PS, Turker MS (1995) Genetic alterations on chromosome 17 distinguish types of epithelial ovarian tumors. Hum Pathol 26:393-397
65. Piver MS, Baker TR, Jishi MF, Sandecki AM, Tsukada Y, Natarajan N, Mettlin CJ, Blake CA (1993) Familial ovarian cancer: a report of 658 families from Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer 71:582-588
66. Powell DE, Puls L, van Nagell I (1992) Current concepts in epithelial ovarian tumors: does benign to malignant transformation occur? Hum Pathol 23:846-847
67. Puls LE, Powell DE, De Priest PD, Gallion HH, Hunter JE, Kryscio RJ (1992) Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 47:53-57
68. Resta L, Russo S, Colucci G, Prat J (1993) Morphologic precursors of ovarian epithelial tumors. Obstet Gynecol 82:181-186
69. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornurotti M, Oriana S, Bohm S, Bresciani GL, Spatti G, Zunino F (1996) A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56:689-693
70. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd I (1993) Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 53:5100-5103
71. Rubin SC, Finstad CL, Federici MG, Scheiner L, Lloyd KO, Hoskin WJ (1994) Prevalence and significance of Her-2/neu expression in early epithelial ovarian cancer. Cancer 73:1456-1459
72. Rubin SC, Benjamin I, Behbakhl K, Takahashi H, Morgan MA, LiVolsi VA, Berchuck A, Muto MG, Garber JE, Weber BL, Lynch HT, Boyd J (1996) Clinicopathologic characteristics of ovarian cancers occurring in women with germline mutations of BRCA1. N Engl J Med 335:1413-1416
73. Russell SEH, Hickey GI, Lowry WS, White P, Atkinson RJ (1990) Allele loss from chromosome 17 in ovarian cancer. Oncogene 5:1581-1583
74. Saito H, Inazawa J, Saito S, Kasumi F, Koi S, Sagal S, Kudo R, Saito J, Noda K, Nakamura Y (1993) Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region in 17q21-3 often and commonly deleted in tumors. Cancer Res 53:3382-3385
75. Saretzki G, Hoffmann U, Röhlke P, Psille R, Gaigal T, Keller G, Höfler H, Löning T, Petersen I, Dietel M (1997) Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome. Cancer 80:1241-1249
76. Sasano H, Comeford J, Silverberg SG, Garret CT (1990) An analysis of abnormalities of the retinoblastoma gene in human ovarian and endometrial carcinoma. Cancer 66:2150-2154
77. Schildkraut JM, Thompson WD (1988) Familial ovarian cancer: a population-based case-control study. Am J Epidemiol 128:456-466
78. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston DM (1997) Association of BRCA-1 with Rad 51 in mitotic and meiotic cells. Cell 88:265-275
79. Sharan SK, Morimatsu M, Albrecht V, Lim DS, Regel E, Dinh Ch, Sands A, Eichele G, Hasty P, Bradley A (1997) Embryonic lethality and radiation hypersensitivity mediated by Rad 51 in mice lacking BRCA-2. Nature 386:804-806
80. Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, Hoskins K, Weber B, Castilla L, Erdos M, Brody L, Friedman L, Ostermeyer E, Szabo C, King MC, Jhanwar S, Offit K, Norton L, Gilewski T, Luhin M, Osborne M, Black D, Boyd M, Steel M, Ingles S, Haile R, Lindblom A, Olsson H, Borg A, Bishop DT, Solomon E, Radice P, Spatti G, Gayther S, Ponder B, Warren W, Stratton M, Liu Q, Fujimura F, Lewis C, Skolnick MM, Goldgar DE (1995) A collaborative survey of 80 mutations in the BRCA-1 breast and ovarian cancer susceptibility gene. JAMA 273:535-541
81. Shelling AN (1997) Role of p53 in drug resistance in ovarian cancer. Lancet 349:744-745
82. Shigemasa K, Hu C, West CM, Clarke J, Parham GP, Parmley TH, Korourian S, Baker VV, O'Brien TJ (1997) p16 overexpression: a potential early indicator of transformation in ovarian carcinoma. J Soc Gynecol Invest 4:95-102
83. Singleton TP, Perrone T, Oakley G, Niehans GA, Carson L, Cha SS, Striekler JG (1994) Activation of c-erb B-2 and prognosis in ovarian carcinoma. Cancer 73:1460-1466
84. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith D, Levin WJ, Stuart SG, Udove J, Ullrich A, Press ME (1989) Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
85. Sobol H, Stoppa-Lyonnet D, Bressac-de-Paillerets B, Peyrat JP, Kerangueven F, Janin N, Noguchi T, Eisinger F, Guinebretiere JM, Jacquemier J, Birnbaum D (1996) Truncation at conserved terminal regions of BRCA-1 protein is associated with highly proliferating hereditary breast cancer. Cancer Res 56:3216-3219
86. Steinback F (1981) Benign, bordeline and malignant serous cystadenomas of the ovary. Pathol Res Pract 172:58-72
87. Takahashi H (1996) Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res 56:2738-2341
88. Takahashi H, Behbakht K, McGovern PE, Chiu HC, Couch FJ, Weber BL, Friedman LS, King MC, Furusato M, LiVolsi VA, Menzin AW, Liu PC, Benjamin I, Morgan MA, King SA, Rebane BA, Cardonick A, Mikuta JJ, Rubin SC, Boyd J (1995) Mutation analysis of the BRCA-1 gene in ovarian cancers. Cancer Res 55:2998-3002
89. Tangir J, Loughride NS, Berkowitz RS, Muto MG, Bell DA, Welch WR, Mok SC (1996) Fragment microsatellite instability in epithelial borderline ovarian tumors. Cancer Res 56:2501-2505
90. Tanner B, Hengstler JG, Luch A, Meinert R, Kreutz E, Arand M, Wilkens C, Hofmann M, Oesch F, Knapstein PG, Becker R (1998) C-myc mRNA expression in epithelial ovarian carcinomas in relation to estrogen receptor status, metastatic spread, survival time, FIGO stage and histologic grade and type. Int J Gynecol Pathol 17:66-74
91. Tibiletti MG, Bernasconi B, Furlan D, Riva C, Trubia M, Buraggi G, Franchi M, Bolis P, Mariani A, Frigerio L, Capella C, Taramelli R (1996) Early involvement of 6q in surface epithelial ovarian tumors. Cancer Res 56:4493-4498
92. Tribodeau SN, Bren G, Schaid V (1993) Microsatellite isntability in cancer of the proximal colon. Science 260:816-819
93. Vogelstein B, Kinzler KW (1994) Has the breast cancer gene been found? Cell 79:1-3
94. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA (1996) Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat Med 2:724-725
95. Watson P, Lynch HT (1993) Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71:677-685
96. Wertherm I, Muto MG, Welch WR, Bell DA, Berkowitz RS, Mok SC (1994) p53 gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst 86:1549-1551
97. Wooster R, Neuhausen S, Mangion J, Quirk Y, Ford D, Collins N. Nguyen K, Seal S, Tran T, Avenill D, Fields P, Marshall G, Narod S, Lenoir GM, Lynch H, Feunteun J, Deville, Cornelisse CJ, Menko FH, Daly PA, Ormiston W, McManus R, Pye C, Lewis CM, Cannon-Albright LA, Peto J, Ponder BAJ, Skolmick MH, Easton DF, Goldgar DE, Stratton MR (1994) Localization of a breast cancer susceptibility gene, BRCA-2 to chromosome 13q 12-13. Science 265:2088-2090
98. Worsley SD, Ponder BAJ, Davies BR (1997) Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol 64:189-195
99. Yamasaki F, Tokunaga O, Sugimori H (1997) Apoptotic index in ovarian carcinoma: correlation with clinicopathologic factors and prognosis. Gynecol Oncol 66:439-448
100. Zheng J, Wan M, Zweizig S, Velicescu M, Yu MC, Dubeau L (1993) Histologically benign or low-grade malignant tumors adjacent to high-grade ovarian carcinomas contain molecular characteristics of high-grade carcinomas. Cancer Res 53:4138-4142